SECTION 1. IDENTIFICATION

Product name : GAVRETO(TM) Capsules 100 mg
Product code : RO749-9790/F02
Common name(s), synonym(s) of the substance : GAVRETO Capsules (hard) 100 mg

Manufacturer or supplier's details
Company name of supplier : Genentech, Inc.
Address : 1 DNA Way
South San Francisco, CA 94080
USA
Telephone : 001-(650) 225-1000
E-mail address : info.sds@roche.com
Emergency telephone number : US Chemtrec phone (800)-424-9300

Recommended use of the chemical and restrictions on use
Recommended use : Formulated pharmaceutical active substance
Restrictions on use : For professional users only.

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)
Carcinogenicity : Category 2
Reproductive toxicity : Category 2
Specific target organ toxicity - repeated exposure : Category 2 (Cardiovascular, Skeleton, hematopoietic system)

GHS label elements
Hazard pictograms : 

Signal Word : Warning
Hazard Statements : H351 Suspected of causing cancer.
H361d Suspected of damaging the unborn child.
H373 May cause damage to organs (Cardiovascular, Skeleton, hematopoietic system) through prolonged or repeated exposure.
Precautionary Statements:

**Prevention:**
- P201 Obtain special instructions before use.
- P202 Do not handle until all safety precautions have been read and understood.
- P260 Do not breathe dust/ fume/ gas/ mist/ vapors/ spray.
- P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**
- P308 + P313 IF exposed or concerned: Get medical advice/ attention.

**Storage:**
- P405 Store locked up.

**Disposal:**
- P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards**
None known.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

**Substance / Mixture**
Mixture

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pralsetinib</td>
<td>2097132-94-8</td>
<td>21.8</td>
</tr>
<tr>
<td>Cellulose, 2-hydroxypropyl methyl ether</td>
<td>9004-65-3</td>
<td>&gt;= 20.0 - &lt;= 25.0</td>
</tr>
<tr>
<td>Carbonic acid sodium salt (1:1)</td>
<td>144-55-8</td>
<td>&gt;= 15.0 - &lt;= 20.0</td>
</tr>
<tr>
<td>1,2,3-Propanetricarboxylic acid, 2-hydroxy-</td>
<td>77-92-9</td>
<td>&gt;= 5.0 - &lt; 10.0</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>&gt;= 5.0 - &lt; 10.0</td>
</tr>
<tr>
<td>Octadecanoic acid, magnesium salt (2:1)</td>
<td>557-04-0</td>
<td>&lt; 1.0</td>
</tr>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>&gt;= 1.0 - &lt; 5.0</td>
</tr>
<tr>
<td>Titanium oxide (TiO2)</td>
<td>13463-67-7</td>
<td>&lt; 0.5</td>
</tr>
<tr>
<td>non hazardous compounds</td>
<td>Not Assigned</td>
<td>&gt; 20.0</td>
</tr>
</tbody>
</table>

### SECTION 4. FIRST AID MEASURES

**General advice**
Move out of dangerous area.
Show this material safety data sheet to the doctor in attendance.
Do not leave the victim unattended.

**If inhaled**
Move to fresh air.
If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.
In case of skin contact: If on skin, rinse well with water.

In case of eye contact: Immediately flush eye(s) with plenty of water. Remove contact lenses. Protect unharmed eye. Keep eye wide open while rinsing. If eye irritation persists, consult a specialist.

If swallowed: Keep respiratory tract clear. Do not give milk or alcoholic beverages. Never give anything by mouth to an unconscious person. If symptoms persist, call a physician. Take victim immediately to hospital. Rinse mouth with water.

Most important symptoms and effects, both acute and delayed: Suspected of causing cancer. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.

Notes to physician: The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media: High volume water jet

Specific hazards during fire fighting: Do not allow run-off from fire fighting to enter drains or water courses.

Hazardous combustion products: In case of fire hazardous decomposition products may be produced such as: Carbon monoxide Hydrogen fluoride Carbon oxides

Further information: Collect contaminated fire extinguishing water separately. This must not be discharged into drains. Fire residues and contaminated fire extinguishing water must be disposed of in accordance with local regulations.

Special protective equipment for fire-fighters: Wear self-contained breathing apparatus for firefighting if necessary.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Avoid dust formation. Avoid breathing dust. Avoid exposure
Environmental precautions: Prevent product from entering drains. Prevent further leakage or spillage if safe to do so. If the product contaminates rivers and lakes or drains inform respective authorities.

Methods and materials for containment and cleaning up: Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion: Avoid dust formation. Provide appropriate exhaust ventilation at places where dust is formed.

Advice on safe handling: Avoid formation of respirable particles. Do not breathe vapors/dust. Avoid exposure - obtain special instructions before use. Avoid contact with skin and eyes. For personal protection see section 8. Smoking, eating and drinking should be prohibited in the application area. Dispose of rinse water in accordance with local and national regulations.

Conditions for safe storage: Keep container tightly closed in a dry and well-ventilated place. Electrical installations / working materials must comply with the technological safety standards.

Further information on storage conditions: See label, package insert or internal guidelines.

Storage temperature: Protected from heat and light. Protect from moisture.

Further information on storage stability: No decomposition if stored and applied as directed.

Packaging material: Suitable material: Stainless steel, glass, Plastic container of HDPE.

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pralsetinib</td>
<td>2097132-94-8</td>
<td>IOEL</td>
<td>0.003 mg/m³</td>
<td>Roche Industrial Hygiene Committee</td>
</tr>
</tbody>
</table>
### Engineering measures

- **No data available**

### Personal protective equipment

#### Respiratory protection

- In the case of dust or aerosol formation use respirator with an approved filter.
- Effective dust mask

#### Hand protection

- In case of contact through splashing:
SAFETY DATA SHEET

GAVRETO(TM) Capsules 100 mg

Version 1.2 Revision Date: 04-20-2021 Date of last issue: 12-03-2020

Date of first issue: 11-30-2020

Material: Nitrile rubber
Break through time: > 30 min
Glove thickness: > 0.11 mm

In case of full contact:
Material: butyl-rubber
Break through time: > 480 min
Glove thickness: > 0.4 mm

Remarks:
Wear appropriate protective gloves to prevent skin contact.
Replace torn or punctured gloves promptly.

Eye protection:
Eye wash bottle with pure water
Tightly fitting safety goggles

Skin and body protection:
Choose body protection according to the amount and concentration of the dangerous substance at the work place.

Protective measures:
Instruction of employees mandatory

Hygiene measures:
When using do not eat or drink.
When using do not smoke.
Wash hands before breaks and at the end of workday.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: capsules
Color: light blue
Odor: Not applicable
Odor Threshold: Not applicable
pH: Not applicable
Melting point/range: No data available
Boiling point/boiling range: No data available
Evaporation rate: No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapor pressure: No data available
Relative vapor density : Not applicable
Relative density : No data available
Solubility(ies)
Water solubility : No data available
Solubility in other solvents : No data available
Partition coefficient: n-octanol/water : No data available
Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity
Viscosity, dynamic : Not applicable
Viscosity, kinematic : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No dangerous reaction known under conditions of normal use.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : No decomposition if stored and applied as directed.
Conditions to avoid : No data available
Incompatible materials : No data available
Hazardous decomposition products : No data available

SECTION 11. TOXICOLOGICAL INFORMATION

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Expert judgment
Acute inhalation toxicity : Acute toxicity estimate: > 200 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method
Acute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method
SAFETY DATA SHEET

GAVRETO(TM) Capsules 100 mg

Version 1.2  
Revision Date: 04-20-2021  
Date of last issue: 12-03-2020  
Date of first issue: 11-30-2020

Components:

Pralsetinib:
Acute oral toxicity: LD50 Oral (Rat): > 300 mg/kg  
GLP: yes  
NOAEL (No observed adverse effect level) (Rat): 300 mg/kg  
GLP: yes

1,2,3-Propanetricarboxylic acid, 2-hydroxy-:
Acute oral toxicity: LD50 Oral (Rat): > 6,730 mg/kg  
LD50 Oral (Rabbit): > 7,000 mg/kg  
LD50 Oral (Mouse): 5,400 mg/kg

Cellulose:
Acute oral toxicity: LD50 Oral (Rat): > 5,000 mg/kg

Starch:
Acute oral toxicity: Acute toxicity estimate: > 5,001 mg/kg  
Method: Expert judgment

Acute inhalation toxicity: Acute toxicity estimate: > 30 mg/l  
Test atmosphere: dust/mist  
Method: Expert judgment

Acute dermal toxicity: Acute toxicity estimate: > 5,001 mg/kg  
Method: Expert judgment

Titanium oxide (TiO2):
Acute oral toxicity: LD50 (Rat): > 7,500 mg/kg

Octadecanoic acid, magnesium salt (2:1):
Acute oral toxicity: LD50 Oral (Rat): > 2,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:

1,2,3-Propanetricarboxylic acid, 2-hydroxy-:
Remarks: May cause skin irritation in susceptible persons.
Serious eye damage/eye irritation
Not classified based on available information.

**Components:**

1,2,3-Propanetricarboxylic acid, 2-hydroxy-

Result: Irritating to eyes.
Remarks: May cause irreversible eye damage.

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

**Components:**

**Pralsetinib:**

Genotoxicity in vitro: Test Type: Ames test
Method: OECD Test Guideline 471
Result: negative
GLP: yes

Genotoxicity in vivo: Test Type: Micronucleus test
Method: OECD Test Guideline 474
Result: negative
GLP: yes

Carcinogenicity
Suspected of causing cancer.

**Components:**

**Cellulose:**

Remarks: No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

IARC
Group 2B: Possibly carcinogenic to humans
Titanium oxide (TiO2) 13463-67-7

OSHA
No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

NTP
No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
Suspected of damaging the unborn child.
Components:

Pralsetinib:
Effects on fetal development:
- Test Type: reproductive and developmental toxicity study
- Species: Rat, male and female
- Application Route: Oral
- Target Organs: Kidney
- Result: Teratogenic potential.
- GLP: yes

- Test Type: reproductive and developmental toxicity study
- Species: Rat, male and female
- Application Route: Oral
- Target Organs: Skeleton
- Result: Teratogenic potential.
- GLP: yes

- Test Type: reproductive and developmental toxicity study
- Species: Rat, male and female
- Application Route: Oral
- Target Organs: Urinary tract
- Result: Teratogenic potential.
- GLP: yes

- Test Type: reproductive and developmental toxicity study
- Species: Rat, male and female
- Application Route: Oral
- Target Organs: Testes
- Result: Teratogenic potential.
- GLP: yes

Reproductive toxicity - Assessment:
- Suspected human reproductive toxicant
  - Suspected of damaging the unborn child.

STOT-single exposure
Not classified based on available information.

Components:

Starch:
Assessment:
- The substance or mixture is not classified as specific target organ toxicant, single exposure.

Octadecanoic acid, magnesium salt (2:1):
Assessment:
- The substance or mixture is not classified as specific target organ toxicant, single exposure.

STOT-repeated exposure
May cause damage to organs (Cardiovascular, Skeleton, hematopoietic system) through prolonged or repeated exposure.
Components:

Pralsetinib:
Target Organs: Cardiovascular
Assessment: May cause damage to organs through prolonged or repeated exposure.

Target Organs: Skeleton
Assessment: May cause damage to organs through prolonged or repeated exposure.

Target Organs: hematopoietic system
Assessment: May cause damage to organs through prolonged or repeated exposure.

Starch:
Assessment: The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Octadecanoic acid, magnesium salt (2:1):
Assessment: The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Repeated dose toxicity

Components:

Pralsetinib:
Species: Rat
Application Route: Oral
Exposure time: 13 Weeks
GLP: yes

1,2,3-Propanetricarboxylic acid, 2-hydroxy-:
NOAEL: 4,000 mg/kg
Exposure time: 5d
Number of exposures: 1

Aspiration toxicity
Not classified based on available information.

Components:

Starch:
No data available

Octadecanoic acid, magnesium salt (2:1):
No data available
SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

1,2,3-Propanetricarboxylic acid, 2-hydroxy-:

Toxicity to fish : LC0 (Carassius auratus (goldfish)): 625 mg/l
Toxicity to daphnia and other aquatic invertebrates : LC100 (Daphnia magna (Water flea)): 85 mg/l
Toxicity to algae/aquatic plants : EC0 (Scenedesmus quadricauda (Green algae)): 640 mg/l
Toxicity to microorganisms : EC0 (Pseudomonas putida): > 10,000 mg/l
Exposure time: 16 h

Ecotoxicology Assessment

Acute aquatic toxicity : This product has no known ecotoxicological effects.
Chronic aquatic toxicity : This product has no known ecotoxicological effects.
Toxicity Data on Soil : Not expected to adsorb on soil.
Other organisms relevant to the environment : No data available

Cellulose:

Ecotoxicology Assessment

Acute aquatic toxicity : This product has no known ecotoxicological effects.
Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Starch:

Toxicity to fish : LC50: > 100 mg/l
Exposure time: 96 h

Ecotoxicology Assessment

Acute aquatic toxicity : This product has no known ecotoxicological effects.
Chronic aquatic toxicity : This product has no known ecotoxicological effects.
Toxicity Data on Soil : Not expected to adsorb on soil.
Other organisms relevant to the environment : No data available

Titanium oxide (TiO2):

Toxicity to fish : LC0 (Leuciscus idus (Golden orfe)): > 1,000 mg/l
Exposure time: 48 h
Toxicity to daphnia and other aquatic invertebrates:
EC0 (Daphnia magna (Water flea)): 3 mg/l
Exposure time: 720 h

Ecotoxicology Assessment
Toxicity Data on Soil:
Not expected to adsorb on soil.

Other organisms relevant to the environment:
No data available

Octadecanoic acid, magnesium salt (2:1):

Ecotoxicology Assessment
Acute aquatic toxicity:
This product has no known ecotoxicological effects.

Chronic aquatic toxicity:
This product has no known ecotoxicological effects.

Toxicity Data on Soil:
Not expected to adsorb on soil.

Other organisms relevant to the environment:
No data available

Persistence and degradability

Components:

1,2,3-Propanetricarboxylic acid, 2-hydroxy-:
Biodegradability:
Biodegradation: 98 %
Exposure time: 7 d
Method: OECD Test Guideline 302B

Bioaccumulative potential

Components:

Pralsetinib:
Partition coefficient: n-octanol/water:
log Pow: 3.0 (68 °F / 20 °C)
pH: 5
Method: OECD Test Guideline 107
GLP: yes

log Pow: 4.0 (68 °F / 20 °C)
pH: 7
Method: OECD Test Guideline 107
GLP: yes

log Pow: 3.9 (68 °F / 20 °C)
pH: 9
Method: OECD Test Guideline 107
GLP: yes

1,2,3-Propanetricarboxylic acid, 2-hydroxy-:
Partition coefficient: n-octanol/water:
log Pow: -1.72
Cellulose:
Partition coefficient: n-octanol/water : Remarks: No data available

Starch:
Partition coefficient: n-octanol/water : Remarks: No data available

Titanium oxide (TiO2):
Partition coefficient: n-octanol/water : Remarks: No data available

Octadecanoic acid, magnesium salt (2:1):
Partition coefficient: n-octanol/water : log Pow: 0.8
Method: OECD Test Guideline 107

Mobility in soil
No data available

Other adverse effects

Product:
Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82
Protection of Stratospheric Ozone - CAA Section 602 Class I Substances
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Do not contaminate ponds, waterways or ditches with chemical or used container.
Send to a licensed waste management company.

Contaminated packaging : Empty remaining contents.
Dispose of as unused product.
Empty containers should be taken to an approved waste handling site for recycling or disposal.
Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION

International Regulations
UNRTDG
### SAFETY DATA SHEET

**GAVRETO(TM) Capsules 100 mg**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.2</td>
<td>04-20-2021</td>
<td>12-03-2020</td>
<td>11-30-2020</td>
</tr>
</tbody>
</table>

- Not regulated as a dangerous good
- **IATA-DGR**
  - Not regulated as a dangerous good
- **IMDG-Code**
  - Not regulated as a dangerous good
- **Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**
  - Not applicable
- **Domestic regulation**
- **49 CFR**
  - Not regulated as a dangerous good

### SECTION 15. REGULATORY INFORMATION

**CERCLA Reportable Quantity**
This material does not contain any components with a CERCLA RQ.

**SARA 304 Extremely Hazardous Substances Reportable Quantity**
This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**
This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards**

| Carcinogenicity |
| Reproductive toxicity |
| Specific target organ toxicity (single or repeated exposure) |

**SARA 313**

- This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

**Clean Air Act**
This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B). This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61). This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F). This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMI Intermediate or Final VOC's (40 CFR 60.489).

**Clean Water Act**
This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A. This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3. This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307 This product does not contain any priority pollutants related to the U.S. Clean Water Act

**US State Regulations**

**Massachusetts Right To Know**
SAFETY DATA SHEET

GAVRETO(TM) Capsules 100 mg

Version 1.2  Revision Date: 04-20-2021  Date of last issue: 12-03-2020
Date of first issue: 11-30-2020

Cellulose  9004-34-6
Starch  9005-25-8
Titanium oxide (TiO2)  13463-67-7

Pennsylvania Right To Know
Cellulose, 2-hydroxypropyl methyl ether  9004-65-3
Pralsetinib  2097132-94-8
non hazardous compounds  Not Assigned
Carbonic acid sodium salt (1:1)  144-55-8
1,2,3-Propanetricarboxylic acid, 2-hydroxy-
Cellulose  9004-34-6
Starch  9005-25-8
Titanium oxide (TiO2)  13463-67-7

Maine Chemicals of High Concern
Product does not contain any listed chemicals

Vermont Chemicals of High Concern
Product does not contain any listed chemicals

Washington Chemicals of High Concern
Product does not contain any listed chemicals

California Prop. 65
WARNING: This product can expose you to chemicals including Titanium oxide (TiO2), which is/are known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

California Permissible Exposure Limits for Chemical Contaminants
Cellulose  9004-34-6
Starch  9005-25-8
Titanium oxide (TiO2)  13463-67-7

The ingredients of this product are reported in the following inventories:

DSL: This product contains the following components that are not on the Canadian DSL nor NDSL.

Pralsetinib

non hazardous compounds

AICS: Not in compliance with the inventory

NZIoC: Not in compliance with the inventory

ENCS: Not in compliance with the inventory

ISHL: Not in compliance with the inventory

KECI: Not in compliance with the inventory

PICCS: Not in compliance with the inventory

IECSC: Not in compliance with the inventory

TCSI: Not in compliance with the inventory

TSCA: Product contains substance(s) not listed on TSCA inventory.
TSCA list
No substances are subject to a Significant New Use Rule.
No substances are subject to TSCA 12(b) export notification requirements.

**SECTION 16. OTHER INFORMATION**

**NFPA 704:**

<table>
<thead>
<tr>
<th>Flammability</th>
<th>Health</th>
<th>Instability</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

**HMIS® IV:**

<table>
<thead>
<tr>
<th>HEALTH</th>
<th>FLAMMABILITY</th>
<th>PHYSICAL HAZARD</th>
</tr>
</thead>
<tbody>
<tr>
<td>*</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

**Full text of other abbreviations**

- **ACGIH**: USA. ACGIH Threshold Limit Values (TLV)
- **NIOSH REL**: USA. NIOSH Recommended Exposure Limits
- **OSHA P0**: USA. OSHA - TABLE Z-1 Limits for Air Contaminants - 1910.1000
- **OSHA Z-1**: USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
- **ACGIH / TWA**: 8-hour, time-weighted average
- **NIOSH REL / TWA**: Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
- **OSHA P0 / TWA**: 8-hour time weighted average
- **OSHA Z-1 / TWA**: 8-hour time weighted average

**AICS** - Australian Inventory of Chemical Substances; **AIIC** - Australian Inventory of Industrial Chemicals; **ASTM** - American Society for the Testing of Materials; **bw** - Body weight; **CERCLA** - Comprehensive Environmental Response, Compensation, and Liability Act; **CMR** - Carcinogen, Mutagen or Reproductive Toxicant; **DIN** - Standard of the German Institute for Standardisation; **DOT** - Department of Transportation; **DSL** - Domestic Substances List (Canada); **ECx** - Concentration associated with x% response; **EHS** - Extremely Hazardous Substance; **ELx** - Loading rate associated with x% response; **EmS** - Emergency Schedule; **ENCS** - Existing and New Chemical Substances (Japan); **ErCx** - Concentration associated with x% growth rate response; **ERG** - Emergency Response Guide; **GHS** - Globally Harmonized System; **GLP** - Good Laboratory Practice; **HMIS** - Hazardous Materials Identification System; **IARC** - International
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 2004